



**UNIVERSITY OF LEEDS**

This is a repository copy of *Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis*.

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/160719/>

Version: Accepted Version

---

**Article:**

Manzano, A [orcid.org/0000-0001-6277-3752](https://orcid.org/0000-0001-6277-3752), Eskyte, I [orcid.org/0000-0001-9486-0033](https://orcid.org/0000-0001-9486-0033), Ford, HL et al. (8 more authors) (2020) Impact of communication on first treatment decisions in people with relapsing-remitting multiple sclerosis. *Patient Education and Counseling*. ISSN 0738-3991

<https://doi.org/10.1016/j.pec.2020.05.014>

---

© 2020 Elsevier B.V. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Table 3: Activity phases of Relapsing Remitting Multiple Sclerosis**

<b>PHASE</b>	<b>CLINICAL INDICATORS</b>
<b>Stable ("inactive)</b>	No new relapses in the last 12 months
<b>Active</b>	At least two relapses in the last 12-24 months
<b>Highly active</b>	New or ongoing relapses in the last 12 months, when taking a disease modifying treatment like Beta-interferon.
<b>Rapidly evolving severe</b>	At least 2 relapses in the previous year and at least 1 T1 gadolinium-enhancing lesion at baseline MRI

Source: NICE (2019) Disease-modifying therapies for multiple sclerosis.[2]